Physicians' Academy for Cardiovascular Education
During the last 30 years, clinical characteristics of HF patients have changed; nowadays, obesity is common in HF. Dr. Packer explains why obesity plays such an important role in HFpEF.
Based on a case description, prof. van der Meer explains how to diagnose HFpEF based on amyloidosis. Futhermore, he talks about current and future treatments options for patients with transthyretin amyloid cardiomyopathy.
Prof. McMurray gives an update on where we are today in the prevention of HF in diabetes patients with new diabetes drugs and talks about the next steps of treating HF in patients with and without diabetes.
Slides as educational service to PACE members and meeting participants
Slides as educational service to PACE members and meeting participants
Slides as educational service to PACE members and meeting participants
